Zejula

Zejula Warnings and Precautions

• Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML): MDS/AML has occurred in patients treated with Zejula, some fatal. Patients should be monitored for hematological toxicity, and Zejula discontinued if MDS/AML is confirmed.
• Bone marrow suppression: Complete blood counts should be checked weekly for the first month, monthly for the next 11 months, and periodically thereafter.
• Cardiovascular effects: Hypertension and cardiovascular events have been reported; blood pressure should be monitored.
• Embryo-fetal toxicity: Zejula can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 6 months after the last dose.
• Lactation: Breastfeeding is not recommended during treatment and for 1 month after the final dose.

How to Access Zejula in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Zejula to India?

Zejula (niraparib) capsules may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:

• A valid prescription from a qualified oncologist
• The patient's diagnostic reports, including HRD or BRCA mutation status and response to platinum-based chemotherapy
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.

Is Zejula available in India?

Zejula (niraparib capsules) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Zejula is not commercially marketed in India.

However, patients in India can legally access Zejula through the Named Patient Program (NPP) — an import provision that allows patients to receive medicines approved in other countries but not yet marketed in India, under a doctor's prescription and proper regulatory documentation.

Zejula received US FDA approval in 2017 as a PARP inhibitor for maintenance treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer, ensuring full transparency throughout the process.

Zejula can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.

Sourcing & Delivery of Zejula

Zejula is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant logistics to preserve product integrity from dispatch to delivery.

• Storage maintained at 15°C to 30°C throughout transit
• Real-time shipment tracking and delivery updates
• Delivery coordinated directly with the patient, family, or treating hospital

Availability of Zejula Across Major Cities in India

Named Patient Program supports access to Zejula for patients with ovarian, fallopian tube, and primary peritoneal cancer across major cities in India, coordinating documentation, sourcing, and delivery with treating oncologists.

Mumbai

Patients in Mumbai can access Zejula through NPP with support from treating gynecologic oncologists at the city's leading cancer centers.

Delhi

In Delhi, NPP coordinates with hospitals and specialty oncology clinics to facilitate timely access to Zejula for eligible patients.

Bangalore

Bangalore's oncology and genetics centers work with NPP to support patients requiring Zejula based on HRD or BRCA mutation status.

Chennai

Patients in Chennai can access Zejula through NPP, with coordination between treating doctors and the program's regulatory and logistics team.

Hyderabad

Hyderabad's oncology and genetic testing centers support diagnosis and access coordination for Zejula through NPP.

Kolkata

NPP facilitates access to Zejula for patients in Kolkata under the guidance of treating oncologists.

Pune

Patients in Pune can access Zejula through NPP with prescription-based coordination and delivery support.

Ahmedabad

NPP supports access to Zejula for patients in Ahmedabad, working directly with treating specialists.

Kochi

Patients in Kochi and across Kerala can access Zejula through NPP's regulated import pathway.

Chandigarh

NPP coordinates access to Zejula for patients in Chandigarh and the surrounding region.

Jaipur

Patients in Jaipur can access Zejula through NPP with support from treating oncologists.

Lucknow

NPP facilitates access to Zejula for patients in Lucknow and across Uttar Pradesh.

Bhubaneswar

Patients in Bhubaneswar can access Zejula through NPP's coordinated import and delivery process.

Guwahati

NPP supports access to Zejula for patients in Guwahati and across the Northeast region.

NPP also supports access for patients in other Indian cities not listed above — contact the team to check availability and timelines for your location.